Abortion is back at the Supreme Court Tuesday. This time anti-abortion doctors are challenging the FDA’s regulatory actions making abortion pills more accessible.
More than half of American women who choose to terminate a pregnancy do so using a two-drug combination of pills. So you might call this case “daughter of Dobbs,” the Supreme Court’s 2022 decision reversing Roe v. Wade and leaving the legality of abortion to the states.
Only this time, there is more at stake than abortion rights. It’s the entire structure of the FDA’s regulatory power to approve drugs and continually evaluate their safety—a system that until now has been widely viewed as the gold standard for both safety and innovation.
Arguments will begin at 10AM ET-7AM/PT.
